(NASDAQ: IBRX) Immunitybio's forecast annual revenue growth rate of 225.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 60.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.86%.
Immunitybio's revenue in 2025 is $14,745,000.On average, 3 Wall Street analysts forecast IBRX's revenue for 2025 to be $90,868,544,653, with the lowest IBRX revenue forecast at $78,107,024,378, and the highest IBRX revenue forecast at $101,132,893,235. On average, 3 Wall Street analysts forecast IBRX's revenue for 2026 to be $241,797,226,255, with the lowest IBRX revenue forecast at $158,194,034,514, and the highest IBRX revenue forecast at $333,695,875,567.
In 2027, IBRX is forecast to generate $443,525,344,178 in revenue, with the lowest revenue forecast at $307,469,598,697 and the highest revenue forecast at $544,922,804,475.